Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonicog alfa - Takeda

Drug Profile

Vonicog alfa - Takeda

Alternative Names: BAX 111; Recombinant von Willebrand factor; rVWF; SHP-677; VEYVONDI; Vonvendi

Latest Information Update: 03 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Delbruck Center for Molecular Medicine
  • Developer Takeda
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Von willebrand factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Von Willebrand disease

Most Recent Events

  • 01 Apr 2019 Phase-III clinical trials in Von Willebrand disease (Prevention, In adolescents, In children) in USA (IV) (NCT03879135)
  • 01 Apr 2019 Takeda initiates enrolment in a phase IIIb trial for Von willebrand disease (In children, In adolescents) in USA (NCT03879135)
  • 28 Jan 2019 Baxalta plans a phase IIIb trial for Von willebrand disease (In children, In adults) in Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Italy, Netherlands, Russia, Spain, Turkey, Ukraine, in the UK and US in January 2019 (IV) (EudraCT2018-003453-16) (NCT03879135)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top